BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models

BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models

Standard therapy for high-grade ovarian carcinoma includes surgery followed by platinum-based chemotherapy and poly-ADP ribose polymerase inhibitors (PARPis). Deficiency in homologous recombination repair (HRD) characterizes almost half of high-grade ovarian carcinomas and is due to genetic and epig...

Full description

Bibliographic Details
Main Authors: Federica Guffanti, Ilaria Mengoli, Maria Francesca Alvisi, Giulia Dellavedova, Raffaella Giavazzi, Robert Fruscio, Eliana Rulli, Giovanna Damia
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-06-01
Series:Frontiers in Pharmacology
Subjects:
ovarian cancer
BRCA1 foci
homologous recombination deficiency testing
biomarker
drug resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1390116/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1390116/full

Similar Items